GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (NAS:DNTH) » Definitions » Net Income From Continuing Operations

Dianthus Therapeutics (Dianthus Therapeutics) Net Income From Continuing Operations : $-39.07 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Dianthus Therapeutics Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Dianthus Therapeutics's net income from continuing operations for the three months ended in Mar. 2024 was $-13.75 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was $-39.07 Mil.

Dianthus Therapeutics Net Income From Continuing Operations Historical Data

The historical data trend for Dianthus Therapeutics's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dianthus Therapeutics Net Income From Continuing Operations Chart

Dianthus Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Net Income From Continuing Operations
-13.11 -28.48 -43.56

Dianthus Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Net Income From Continuing Operations Get a 7-Day Free Trial -10.12 -7.09 -14.76 -10.56 -13.75

Dianthus Therapeutics Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dianthus Therapeutics (Dianthus Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (NAS:DNTH) » Definitions » Net Income From Continuing Operations
Comparable Companies
SELB INZY IKNA MACK CBUS PSTX ALVR STOK TCRX ATXS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
87E:Germany
Address
7 Times Square, 43rd Floor, New York, NY, USA, 10036
Website
https://www.dianthustx.com
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is comprised of an experienced team of biotech and pharma executives who are leading the next generation of antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune diseases.

Dianthus Therapeutics (Dianthus Therapeutics) Headlines

From GuruFocus

Fairmount Funds Management LLC Acquires New Stake in Dianthus Therapeutics Inc

By GuruFocus Research • 09-29-2023

Insider Buying: Fairmount Funds Management LLC Acquires 24,254 Shares of Dianthus Therapeutics Inc

By GuruFocus Research • 09-14-2023